DSP-5336 is a small molecule currently under phase I/II clinical development (DSP-5336-101 trial) enrolling adult patients with R/R AML or ALL and dose-expansion cohorts enrolling patients with R/R AML with KMT2Ar or NPM1-m. Here, NPM1 is linked to acute myeloid leukemia.